Alendronic acid

Alendronic acid is indicated for the-

• Treatment of Osteoporosis in Postmenopausal Women: Alendronic acid is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, Alendronic acid increases bone mass and reduces the incidence of fractures, including those of the hip and spine.
• Prevention of Osteoporosis in Postmenopausal Women: Alendronic acid is indicated for the prevention of postmenopausal osteoporosis.
• Treatment to Increase Bone Mass in Men with Osteoporosis: Alendronic acid is indicated for treatment to increase bone mass in men with osteoporosis.
• Treatment of Glucocorticoid-Induced Osteoporosis: Alendronic acid is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density.
• Treatment of Paget's Disease of Bone: Alendronic acid is indicated for the treatment of Paget’s disease of bone in men and women. Treatment is indicated in patients with Paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.